Supplemental Material

Autophagy: A Novel Mechanism Involved in the Anti-Inflammatory Abilities of Probiotics

Mazen Zaylaa[a,b] Jeanne Alard[a] Imad Al Kassaa[b] Veronique Peucelle[a] Denise Boutillier[a] Jérémy Desramaut[a] Philip Rosenstiel[c] Hang T. T. Nguyen[d] Fouad Dabboussi[b] Bruno Pot[a] Corinne Grangette[a]

[a]University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, Lille, France, [b]Laboratoire de Microbiologie Santé et Environnement (LMSE), Doctoral School of Sciences and Technology, Faculty of Public Health, Lebanese University, Tripoli, Lebanon, [c]University of Kiel, University Hospital Schleswig Holstein, Kiel, Germany, [d]M2iSH, Inserm U1071, INRA USC 2018, Université Clermont Auvergne, Clermont-Ferrand, France

Supplementary Figure legends

Figure S1. PBMCs (A) or BMDCs (B) pretreated or not for 1h with 3-MA or *atgl16l1*-deficient (KO) BMDCs were stimulated with the bacteria at a bacteria/cells ratio of 10:1 or with Rapamycin (10 μg/ml) for 4 h. The autophagy was followed by immunoblot analysis using antibodies against LC3 to analyze the LC3-II conversion.



– + 3-MA – + 3-MA – + 3-MA – + 3-MA

NS

B. bifidum IPL A7.31

B. longum CMUL CXL 001

L. rhamnosus IPL A2.21



– + 3-MA – + 3-MA – + 3-MA – + 3-MA

L. gasseri IPL A6.33

L. reuteri 100.23

L. gasseri *CMUL 057*

L. acidophilus CMUL 067

– + 3-MA KO – + 3-MA KO – + 3-MA KO

NS

B. longum CMUL CXL 001

L. rhamnosus IPL A2.21

– + 3-MA KO – + 3-MA KO – + 3-MA KO

Rapamycin

L. gasseri IPL A6.33

L. reuteri 100.23